RxDoctor Payments Data

Maria Lugo, MD

Family Medicine · Columbus, NJNPI 1669488375

Payments from drug & device makers

$2,216in general payments, 2019–2025

Across 70 payments — averaging $31.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$493
  • Phathom Pharmaceuticals, Inc.$358
  • Novo Nordisk$244
  • Exact Sciences$146
  • Lundbeck LLC$125
  • Axsome Therapeutics, Inc.$122
  • plus $728 from 19 others

What the payments were for

  • Food & beverage$2,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,216 in reported general payments places this provider in the 75th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$103,762
Medicare patients
259
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$56,000
JanuviaSitagliptin Phosphate44$50,386
EliquisApixaban41$43,385
MounjaroTirzepatide26$41,280
JardianceEmpagliflozin25$30,582
Janumet XrSitagliptin Phos/Metformin Hcl21$19,060
XareltoRivaroxaban12$7,844
SymbicortBudesonide/Formoterol Fumarate23$5,978
Valsartan134$5,322
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$4,991
Rosuvastatin Calcium337$4,545
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$4,446
Levothyroxine Sodium329$3,569
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide77$3,217
Atorvastatin Calcium252$2,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$80$69,44665 claims
Novo NordiskOzempic$244$56,00033 claims
PfizerEliquis$67$43,38541 claims
Lilly USA, LLCMounjaro$121$41,28026 claims
Boehringer IngelheimJardiance$47$30,58225 claims
AstraZenecaSymbicort$493$5,97823 claims
AbbVieSynthroid$25$2,79928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Columbus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →